公司資料
CervoMed 股價、新聞與催化劑
- 股票代碼:
- CRVO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
2.62 USD (+2.34%)
收盤價
最後更新: 2026年8月21日
27.8M USD
市值
股價為何變動
As of Aug 21, 2026, CRVO closed up 2.34% at $2.62. No new same-company headline was identified in the current news window.
公司概覽
Neuroinflammation and Synaptic Dysfunction
CervoMed develops treatments for age-related brain disorders by targeting mechanisms that impair neuronal signaling. Its lead candidate focuses on p38 alpha MAP kinase, a driver of neuroinflammation and synaptic dysfunction.
Neflamapimod
Neflamapimod is an oral, brain-penetrant small molecule that selectively inhibits p38 alpha. It is intended to restore synaptic function and improve neuronal health in disorders affecting cholinergic brain networks.
Dementia With Lewy Bodies
The Phase 2b RewinD-LB study generated supportive results in dementia with Lewy bodies. CervoMed has selected the Phase 3 formulation and dose and aligned with U.S. and other regulators on a global, approximately 300-patient confirmatory trial.
Additional Neurologic Indications
Phase 2a studies evaluate neflamapimod in recovery after ischemic stroke and non-fluent-variant primary progressive aphasia. The molecule has also been selected for the EXPERTS-ALS platform trial.
未來催化劑
- Initiation of the Phase 3 dementia-with-Lewy-bodies trial expected in the second half of 2026, subject to financing.
- Topline Phase 2a ischemic-stroke-recovery data expected in the second half of 2026.
- Initial topline Phase 2a primary-progressive-aphasia data expected in the second half of 2026.
- Initiation of the EXPERTS-ALS trial expected in the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。